Table 1. Regression analysis of selected chromosomal arm alterations patient/clinical factors.
| Chromosome arm | Risk factors | Odds ratio (95% confidence intervals) | P-value |
|---|---|---|---|
| 1p− | Grade: I, II (REF) vs III, IV | 2.4 (1.3–4.2) | 0.003 |
| Stage: T1 (REF), T2, T3-4 | 1.6 (0.7–3.4); 3.7 (1.6–8.5) | 0.001 | |
| 3p− | VHL gene inactivation: no (REF) vs yes | 1250 (476–3125) | <0.0001 |
| 3q− | BMI: <25 (REF), 25–30, 30+ | 2.5 (1.4–4.6); 1.9 (1.0–3.7) | 0.01 |
| Sex: female (REF) vs male | 2.4 (1.5–4.2) | 0.0004 | |
| 4q− | Grade: I, II (REF), vs III, IV | 2.3 (1.4–3.6) | 0.001 |
| Age: <50 (REF), 50–60, 60+ | 1.6 (0.8–2.9); 3.0 (1.5–5.7) | 0.001 | |
| 5p+ | Grade: I, II (REF), vs III, IV | 1.6 (1.2–3.0) | 0.02 |
| 6q− | Grade: I, II (REF), vs III, IV | 2.1 (1.3–3.3) | 0.004 |
| 7p+ | Grade: I, II (REF), vs III, IV | 2.1 (1.3–3.4) | 0.003 |
| 7q+ | Family history cancer: no (REF) vs yes | 0.6 (0.4–0.9) | 0.02 |
| Grade: I, II (REF), vs III, IV | 2.1 (1.3–3.3) | 0.004 | |
| 8p− | Grade: I, II (REF), vs III, IV | 3.0 (1.8–5.0) | <0.0001 |
| Family history cancer: no (REF) vs yes | 0.6 (0.4–0.9) | 0.01 | |
| 9p− | Grade: I, II (REF), vs III, IV | 2.2 (1.3–3.7) | 0.003 |
| Stage T1 (REF), T2, T3-4 | 3.3 (1.5–7.4); 6.3 (2.6–14.8) | <0.0001 | |
| Age: <50 (REF), 50–60, 60+ | 1.9 (0.9–3.7); 3.1 (1.5–6.3) | 0.006 | |
| Sex: female (REF) vs male | 2.0 (1.2–3.1) | 0.007 | |
| 9q− | Grade: I, II (REF), vs III, IV | 2.5 (1.4–4.2) | 0.001 |
| Stage T1 (REF), T2, T3-4 | 3.9 (1.6–9.2); 7.5 (3.0–18.6) | <0.0001 | |
| Age: <50 (REF), 50–60, 60+ | 1.6 (0.8–3.2); 2.9 (1.4–5.9) | 0.007 | |
| Sex: female (REF) vs male | 2.4 (1.5–4.0) | 0.0006 | |
| 12p+ | Stage T1 (REF), T2, T3-4 | 2.8 (1.2–6.6); 5.0 (2.1–12.2) | 0.001 |
| Sex: female (REF) vs male | 2.1 (1.3–3.7) | 0.005 | |
| 12q+ | Stage T1 (REF), T2, T3-4 | 1.2 (0.9–5.2); 4.8 (2.0–11.9) | 0.001 |
| Grade: I, II (REF), vs III, IV | 2.2 (1.8–4.0) | 0.01 | |
| Sex: female (REF) vs male | 2.3 (1.2–4.4) | 0.01 | |
| 13q− | Stage T1 (REF), T2, T3-4 | 4.4 (1.3–15.1); 13.3(3.8–46.6) | <0.0001 |
| Grade: I, II (REF), vs III, IV | 3.2 (1.9–5.6) | <0.0001 | |
| 14q− | Organic solvents: no (REF) vs yes | 1.9 (1.1–3.2) | 0.03 |
| Sex: female (REF) vs male | 1.9 (1.1–3.1) | 0.03 | |
| Stage T1 (REF), T2, T3-4 | 1.5 (0.8–2.9); 3.1 (1.5–6.7) | 0.006 | |
| Grade: I, II (REF), vs III, IV | 4.4 (2.34–8.2) | <0.0001 | |
| 20q+ | Stage T1 (REF), T2, T3-4 | 1.3 (0.7–2.8); 3.1 (1.5–6.5) | 0.001 |
Abbreviations: BMI, body mass index; VHL, Von Hippel–Lindau gene.
Adjusted for Center, age, sex, stage, grade and VHL gene inactivation.